Baxter Appoints Ludwig Hantson as President, International

DEERFIELD, Ill.--(BUSINESS WIRE)-- Baxter International Inc. (NYSE:BAX) announced today that Ludwig Hantson, Ph.D. has been appointed corporate vice president and president, International. He will assume his new role on Monday, May 3.

Hantson, 47, will be responsible for leading the company’s international operations. Most recently, Hantson was chief executive officer, Pharma North America at Novartis Pharmaceuticals Corporation.

“Geographic expansion continues to be a key growth driver for Baxter. Our global presence and the strength of our local and regional organizations position us to meet the ever increasing demand for healthcare worldwide, particularly for the medically necessary products that we provide,” said Baxter Chairman and Chief Executive Officer Robert L. Parkinson, Jr. “Ludwig brings significant international and scientific knowledge and expertise to Baxter, and he will be a tremendous asset to the company in his new role leading our international business.”

Hantson served in a variety of senior management positions at Novartis since 2001, including leading the company’s specialty pharmaceuticals unit in the United States and European pharmaceuticals operations. Prior to Novartis, he spent 13 years at Janssen Pharmaceutica in roles of increasing responsibility in marketing and clinical R&D.

Hantson received his Ph.D. in Motor Rehabilitation and Physical Therapy from the University of Louvain, Belgium.

Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.


Baxter International Inc.
Media Contact
Deborah Spak, 847-948-2349
Investor Contact
Mary Kay Ladone, 847-948-3371

KEYWORDS:   United States  Belgium  Europe  North America  Illinois

INDUSTRY KEYWORDS:   Health  Biotechnology  Infectious Diseases  Medical Devices  Pharmaceutical  Other Health  General Health



Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.